Compare ADAM & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADAM | ENGN |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | United States | Canada |
| Employees | 221 | 82 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 665.0M | 647.1M |
| IPO Year | N/A | N/A |
| Metric | ADAM | ENGN |
|---|---|---|
| Price | $7.42 | $6.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $9.17 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 591.0K | 544.3K |
| Earning Date | 04-29-2026 | 03-09-2026 |
| Dividend Yield | ★ 12.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.52 | N/A |
| P/E Ratio | $41.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.45 | $2.66 |
| 52 Week High | $8.76 | $12.25 |
| Indicator | ADAM | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.12 | 31.71 |
| Support Level | $6.85 | $6.18 |
| Resistance Level | $7.61 | $7.63 |
| Average True Range (ATR) | 0.23 | 0.64 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 9.62 | 8.01 |
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.